Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
COPD
Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD
The objective of this trial is to evaluate the safety and effectiveness of Targeted Lung Denervation (TLD) for COPD patients using the lung denervation radiofrequency ablation device.
- Trial name
- NCT05799664
- Testing
- TLD, Standard of care
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Hangzhou Broncus Medical Co., Ltd.
Chronic Obstructive Pulmonary Disease
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared…
- Trial name
- NCT02796677
- Testing
- Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg)
- Where
- 163 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,595 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and…
- Trial name
- FAST (NCT01922271)
- Testing
- NVA237, Tiotropium, Salbutamol
- Where
- 14 sites in Germany
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered…
- Trial name
- NCT00400153
- Testing
- Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg)
- Where
- 180 sites in United States, Argentina and 11 more
- Volunteers
- 1,480 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is characterized by a progressive decline in lung function and increased symptoms such as breathlessness/dyspnoea, cough and expectoration.
- Trial name
- COPD Language (NCT01219946)
- Where
- 32 sites in Greece
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)
The study will be conducted in a single-center, randomized, single-blinded, placebo-controlled, dose escalation design with two dose groups.Multiple-dose inhalation of Ciprofloxacin inhale 50 and 75 mg or placebo will be…
- Trial name
- NCT01072942
- Testing
- Ciprofloxacin (Cipro InhaIe, BAYQ3939)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease
Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)
Trial to evaluate the dose response of SCH 527123 in reducing inflammation from an ozone-induced sputum neutrophilia in both healthy subjects and subjects with COPD.
- Trial name
- NCT01068145
- Testing
- SCH 527123
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Disorders
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.
The purpose of this Phase II study is to assess the safety, reactogenicity and immunogenicity of the investigational Non-typeable Haemophilus influenzae (NTHi) vaccine in patients with moderate and severe persistent airflow…
- Trial name
- NCT02075541
- Testing
- NTHi-10-AS01E
- Where
- 14 sites in Sweden, United Kingdom
- Volunteers
- 145 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study compared the effect of indacaterol (300 μg once daily [od]) on exercise endurance with that of placebo in patients with moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT00620022
- Testing
- Indacaterol 300 μg
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 90 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
Adipose Derived Cells for Chronic Obstructive Pulmonary Disease
The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with diagnosed with chronic obstructive pulmonary…
- Trial name
- NCT02041000
- Testing
- Adipose Derived Stem Cells
- Where
- United States
- Sponsor
- Bioheart, Inc.
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with…
- Trial name
- AERIFY-2 (NCT04751487)
- Testing
- Itepekimab SAR440340
- Where
- 238 sites in United States, Argentina and 27 more
- Volunteers
- 1,234 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial was to establish non-inferiority of lung function response to two doses [25 μg (1 capsule) and 50 μg (2 capsules of 25 μg)] salmeterol, administered as the xinafoate salt, in an inhalation…
- Trial name
- NCT02238106
- Testing
- Salmeterol medium dose, Salmeterol low dose, Salmeterol high dose
- Volunteers
- 136 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
The overall objective of this study is to assess the efficacy and safety of treatment with PT003 (GFF MDI), PT005 (FF MDI), PT001 (GP MDI), and open-label tiotropium bromide inhalation powder compared with each other and Placebo…
- Trial name
- NCT01854645
- Testing
- GFF MDI, GP MDI, FF MDI
- Where
- 139 sites in United States, Australia and 1 more
- Volunteers
- 2,103 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma, Chronic Obstructive Pulmonary Disease
ANASA (Patients' Satisfaction With Pulmonary Diseases' Treatment)
The aim of the study is to compare patients' satisfaction from the use of three different inhalation devices by using the FSI-10 questionnaire
- Trial name
- ANASA (NCT01475045)
- Where
- 2 sites in Greece
- Volunteers
- 1,160 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Pulmonary Disease, Chronic Obstructive
A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment
Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) patients who were administered with Long-Acting Beta-Agonist/ Long-Acting Muscarinic Antagonist (LABA/LAMA) (Fixed-dose Combination (FDC) or free combo) or…
- Trial name
- NCT04011475
- Testing
- Tiotropium + Olodaterol, Other LABA/LAMA, LAMA
- Where
- 12 sites in Taiwan
- Volunteers
- 1,617 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD
The purpose of study is to evaluate the efficacy and safety of Benzalkonium Chloride Solution clearing the oral colonized bacterium in hospitalized patients with COPD.
- Trial name
- NCT02269800
- Testing
- Benzalkonium chloride solution, Normal saline
- Volunteers
- 60 people
- Sponsor
- Lustre Pharmaceutical Lab Co., Ltd
Chronic Obstructive Pulmonary Disease
Autologous Bronchial Basal Cell Transplantation for Treatment of COPD
Chronic Obstructive Pulmonary Disease (COPD) is usually characterized by long-term poor airflow, resulting in chronic pulmonary heart disease, chronic respiratory failure or even death.
- Trial name
- NCT03188627
- Testing
- Bronchial basal cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Regend Therapeutics
Chronic Obstructive Pulmonary Disease
Efficacy of DNK333 in Patients With COPD and Cough
This study evaluates the efficacy and safety of two weeks treatment of DNK333 in patients with COPD and cough.
- Trial name
- NCT01287325
- Testing
- DNK333 100 mg twice daily
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 28 people
- Sponsor
- Novartis
COPD
Management of COPD Patients With BoraCare® Remote Monitoring Solution Including BVS3 Early Detection Score for COPD Exacerbations
The goal of this clinical trial is to demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations (experimental group) compared to conventional follow-up alone…
- Trial name
- AUSTRAAL (NCT06523140)
- Testing
- Boracare remote monitoring solution
- Where
- 10 sites in France
- Volunteers
- 380 people
- Sponsor
- Biosency
Chronic Obstructive Pulmonary Disease (COPD)
Advanced Immunological Approach in COPD Exacerbation
Chronic obstructive pulmonary disease (COPD) are characterized by frequent relapses, often resulting from common bacterial infections. Enhancing the immune response in these patients may decrease the frequency of these relapses.
- Trial name
- AIACE (NCT02417649)
- Testing
- Ismigen
- Where
- 13 sites in Italy
- Volunteers
- 288 people
- Sponsor
- Lallemand Pharma AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.